http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012112051-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365 |
| filingDate | 2010-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012112051-A |
| titleOfInvention | DRUGS THROMBRAIN FORMING INHIBITORS |
| abstract | 1. Preparations of thrombus formation containing active ingredients triflusal and clopidogrel bisulfate with a mass ratio of triflusal: clopidogrel bisulfate (100-650) :( 30-150) .2. The preparations according to claim 1, characterized in that said active substances have a triflusal: clopidogrel bisulfate mass ratio (100-600) :( 30-100), preferably (100-600) :( 50-100) .3. The preparations according to claim 1, characterized in that said active ingredients have a mass ratio of triflusal: clopidogrel bisulfate (100-600) :( 92-104), preferably (300-600) :( 92-104). The preparations according to claim 1, characterized in that said active ingredients have a mass ratio of triflusal: clopidogrel bisulfate (250-650) :( 50-150) .5. The drugs according to claim 1, characterized in that the mass ratio of triflusal: clopidogrel bisulfate (285-315) :( 95-105) .6. The drugs according to claim 1, characterized in that the mass ratio of triflusal: clopidogrel bisulfate (570-630) :( 95-105) .7. The preparations according to claim 1, characterized in that said active substances have a triflusal: clopidogrel bisulfate mass ratio (1-20): 1, preferably (3-6): 1, and more preferably 3: 1 or 6: 1.8. The preparations according to claim 1, characterized in that said active ingredients have a mass ratio of triflusal: clopidogrel bisulfate (300-600): 98 ± 5%, preferably 300: 97.875 or 600: 97.875.9. The drugs according to claim 1, characterized in that the single therapeutic dose of the drug contains 130-800 mg of the indicated active ingredients, preferably 130-700 mg. The preparations according to claim 9, characterized in that the single therapeutic dose of said preparation contains 100-600 mg of triflusal and 30-100 mg of clopidogrel bisulfate, preferably 100-600 mg of triflusal and 50-100 mg of clopidogrel bisulfate. |
| priorityDate | 2009-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.